We will promote further
research and development.
There are cases in which a cancer patient is referred to a medical institution under the guise of a free consultation and is billed a high medical fee. This company and its affiliated medical institutions are absolutely not involved in such activities.
We develop highly safe drugs and culture methods that are essential for NKT cell-targeted therapy, perform cell cultures under the guidance of affiliated medical institutions, and provide medical treatments that are not covered by insurance to patients.We will continue to expand our network of affiliated medical institutions and further research and development with an emphasis on evidence.
RIKEN Immune Regenerative Medicine Inc. is engaged in two businesses: a drug discovery business (acquired manufacturing and marketing approval based on the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices) and an advanced regenerative medicine business (approval granted for advanced medicine not covered under insurance based on the Act on the Safety of Regenerative Medicine).
※“RIKNKT” was renamed “RIKEN-NKT” in October 2021.
RIKEN-NKT® is a new standard “immunotherapy” following the three major cancer treatments (surgery, radiotherapy, and anticancer agents).Developed based on NKT cell activation technology that has been researched by public research institutes, the immunotherapy has been commercialized for the first time in Japan through the private sector by RIKEN Immune Regenerative Medicine, a medical technology development company originating from RIKEN. This treatment is completely different from conventional immunotherapy.
It is the fourth type of lymphocyte after T cells, B cells, and NK cells.The name NKT comes from the fact that it has the characteristics of both NK cells and T cells.NKT cells have a strong immune-response enhancement effect, and by directly killing cancer cells and activating the immune system through IFN-γ production, they exert antitumor effects indirectly.We are developing an immuno-cell therapy that targets NKT cells.
It has been shown to be highly effective in preventing recurrence.It is a treatment that binds immunologically active substances to dendritic cells cultured after blood collection and returns them to the body, activating NKT cells in the body and exerting an antitumor effect.
September 30, 2022
April 5, 2022
December 3, 2021
October 29, 2021
October 19, 2021
March 1, 2020
April 2, 2018
July 25, 2016
What immune regenerative medicine
can do for a prosperous future.
June 15, 2022
October 29, 2021
October 20, 2021
September 29, 2021
January 24, 2021
November 25, 2020
November 18, 2020